|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 肛裂临床诊治指南(第三次修订)显示文摘“美国结直肠外科医师协会(American Societyof ColonandRectal Surgeons.ASCRS)”(协会)致力于推进结直肠和肛门疾病的相关理论以及预防和诊疗水平的提高,给患者提供优质的医疗服务。“标准委员会”由协会中在结直肠外科方面有显著专长的成员组成。该委员会的建立是为了引领国际结直肠和肛门疾病诊治的发展,以建立具有循证医学证据的临床诊疗指南。指南是涵盖性的,非指令性的,目的是为临床决策提供信息,而非具体的治疗方法。指南适用于所有相关的医护人员以及希望得到相应指南中疾病的相关诊治信息的患者。 | Farshid Araghizadeh ~ Robin Boushey Sridhar Chalasani George Chang Robert Cima Gary Dunn Daniel Feingold Philip Fleshner Daniel Geisler Jill Genua Sharon Gregorcyk Daniel Herzig Andreas Kaiser Ravin Kumar David Larson Steven Mills John Monson P. Terry Phang Feza Remzi David Rivadeneira Howard Ross Peter Senatore Elin Sigurdson Thomas Stahl Scott Steele Scott Strong Charles Tement Judith Trudel Madhulika Varnna Martin Weiser 丁义江(译) 皇甫少华(译) 丁曙晴(译) | 2013 | 中华胃肠外科杂志2013，16，7： | 70 |
| 2 | 缺血性卒中的一级预防——美国心脏协会/美国卒中协会卒中委员会指南 动脉粥样硬化性周围血管病跨学科工作组、心血管护理委员会、临床心脏病学委员会、营养、体力活动和代谢委员会以及医疗质量和转归研究跨学科工作组共同倡导显示文摘背景和目的本指南提供有关各种确定和潜在的卒中危险因素证据的概述,并提供降低卒中风险的推荐。方法写作组成员由委员会主席根据每位作者先前在相关课题领域中的工作提名,并经美国心脏协会(AHA)卒中委员会科学声明监督委员会批准。写作组采用系统文献回顾(涵盖时间段为2001年最后一次回顾发表到2005年1月),参考先前已发表的指南、个人文件和专家意见来概括现有的证据,指明现有知识的差距;如果合适,则根据标准的AHA标准做出简明的推荐。写作组全体成员在撰写过程中均有很多机会对推荐进行评论并认可这份声明的最终版本。在AHA科学咨询与协调委员会批准之前,本指南已进行过广泛的同行评议。结果对评价个体首次卒中风险的流程图进行评估。根据干预的可能性(不可干预、可干预或潜在可干预)和证据的强度(证据充分或证据不太充分),对首次卒中的危险因素或风险标记物进行分类。不可干预的危险因素包括年龄、性别、出生体重低、人种/种族和遗传因素。证据充分的可干预危险因素包括高血压、主动或被动吸烟、糖尿病、心房颤动和某些其他心脏病、血脂异常、颈动脉狭窄、镰状细胞病、绝经后激素治疗、不良饮食习惯、缺乏体力活动、肥胖和体脂分布。证据不太充分或潜在的可干预危险因素包括代谢综合征、酗酒、药物滥用、口服避孕药、睡眠呼吸障碍、偏头痛、高同型半胱氨酸血症、脂蛋白(a)升高、脂蛋白相关的磷脂酶升高、高凝状态、炎症和感染。对应用阿司匹林进行卒中一级预防的资料进行回顾。结论有大量证据可以用于确定增加首次卒中风险的各种特殊因素和提供降低这种风险的策略。 | Larry B. Goldstein Robert Adams Mark J. Alberts Lawrence J. Appel Lawrence M. Brass Cheryl D. Bushnell Antonio Culebras Thomas J. DeGraba Philip B. Gorelick John R. Guyton Robert G. Hart George Howard Margaret Kelly-Hayes J.V. (Ian) Nixon Ralph L. Sacco 苏克江 高宗恩 | 2006 | 国际脑血管病杂志2006，14，8： | 28 |
| 3 | Transjugular intrahepatic portosystemic shunt in cirrhosis: An exhaustive critical update显示文摘More than five decades after it was originally conceptualized as rescue therapy for patients with intractable variceal bleeding,the transjugular intrahepatic portosystemic shunt(TIPS)procedure continues to remain a focus of intense clinical and biomedical research.By the impressive reduction in portal pressure achieved by this intervention,coupled with its minimally invasive nature,TIPS has gained increasing acceptance in the treatment of complications of portal hypertension.The early years of TIPS were plagued by poor long-term patency of the stents and increased incidence of hepatic encephalopathy.Moreover,the diversion of portal flow after placement of TIPS often resulted in derangement of hepatic functions,which was occasionally severe.While the incidence of shunt dysfunction has markedly reduced with the advent of covered stents,hepatic encephalopathy and instances of early liver failure continue to remain a significant issue after TIPS.It has emerged over the years that careful selection of patients and diligent post-procedural care is of paramount importance to optimize the outcome after TIPS.The past twenty years have seen multiple studies redefining the role of TIPS in the management of variceal bleeding and refractory ascites while exploring its application in other complications of cirrhosis like hepatic hydrothorax,portal hypertensive gastropathy,ectopic varices,hepatorenal and hepatopulmonary syndromes,non-tumoral portal vein thrombosis and chylous ascites.It has also been utilized to good effect before extrahepatic abdominal surgery to reduce perioperative morbidity and mortality.The current article aims to review the updated literature on the status of TIPS in the management of patients with liver cirrhosis. | Sasidharan Rajesh Tom George Cyriac Abby Philips Rizwan Ahamed Sandeep Kumbar Narain Mohan Meera Mohanan Philip Augustine | 2020 | World Journal of Gastroenterology2020，26，37： | 26 |
| 4 | Colorectal cancers in ulcerative colitis from a low-prevalence area for colon cancer显示文摘AIM: To determine the incidence and risk factors for colorectal cancer(CRC) in patients with ulcerative colitis from a low prevalence region for CRC.METHODS: Our prospective database yielded a cohort of 430 patients [age: 44 ± 14.6 years; 248 men(57.7%)] with ulcerative colitis(median disease duration 6, range: 1-39 years) for analysis. Of these, 131(30.5%) had left-sided colitis and 159(37%) extensive colitis. Patients with histologically confirmed CRC within the segment with colitis were compared with those without CRC, to determine the risk factors for the development of CRC.RESULTS: Twelve patients(2.8%) developed CRC. The overall incidence density was 3.56/1000 patient-years of disease- 3/1000 in the first 10 years, 3.3/1000 at 10 to 20 years, and 7/1000 at > 20 years. Three of our 12 patients developed CRC within 8 years of disease onset. On univariate analysis, extensive colitis, longer duration of disease, and poor control of disease were associated with development of CRC. On multivariate analysis, duration of disease and extent of colitis remained significant.CONCLUSION: CRC occurred in 2.8% of patients with ulcerative colitis in our population- an incidence density similar to that in Western countries in spite of a low overall prevalence of colon cancer in our population.The risk increased with extent and duration of disease. | Devendra Desai Sudeep Shah Abhijit Deshmukh Philip Abraham Anand Joshi Tarun Gupta Ramesh Deshpande Varun Khandagale Siji George | 2015 | World Journal of Gastroenterology2015，21，12： | 7 |
| 5 | It is safe to use transdermal glyceryl trinitrate to lower blood pressure in patients with acute ischaemic stroke with carotid stenosis显示文摘Background There is concern that blood pressure(BP)lowering in acute stroke may compromise cerebral perfusion and worsen outcome in the presence of carotid stenosis.We assessed the effect of glyceryl trinitrate(GTN)in patients with carotid stenosis using data from the Efficacy of Nitric Oxide in Stroke(ENOS)Trial.Methods ENOS randomised 4011 patients with acute stroke and raised systolic BP(140-220 mm Hg)to transdermal GTN or no GTN within 48 hours of onset.Those on prestroke antihypertensives were also randomised to stop or continue their medication for 7 days.The primary outcome was the modified Rankin Scale(mRS)at day 90.Ipsilateral carotid stenosis was split:<30%;30-<50%;50-<70%;≥70%.Data are ORs with 95%CIs adjusted for baseline prognostic factors.results 2023(60.5%)ischaemic stroke participants had carotid imaging.As compared with<30%,≥70%ipsilateral stenosis was associated with an unfavourable shift in mRS(worse outcome)at 90 days(OR 1.88,95%CI 1.44 to 2.44,p<0.001).Those with≥70%stenosis who received GTN versus no GTN had a favourable shift in mRS(OR 0.56,95%CI 0.34 to 0.93,p=0.024).In those with 50-<70%stenosis,continuing versus stopping prestroke antihypertensives was associated with worse disability,mood,quality of life and cognition at 90 days.Clinical outcomes did not differ across bilateral stenosis groups.Conclusions Following ischaemic stroke,severe ipsilateral carotid stenosis is associated with worse functional outcome at 90 days.GTN appears safe in ipsilateral or bilateral carotid stenosis,and might improve outcome in severe ipsilateral carotid stenosis. | Jason P Appleton Lisa J Woodhouse Andrew Belcher Daniel Bereczki Eivind Berge Valeria Caso Hui Meng Chang Hanne K Christensen Ronan Collins John Gommans Ann C Laska George Ntaios Serefnur Ozturk Gillian M Sare Szabolcs Szatmari Yongjun Wang Joanna M Wardlaw Nikola Sprigg Philip M Bath for the ENOS investigators | 2019 | Stroke & Vascular Neurology2019，4，1： | 6 |
| 6 | Endoscopic sphincterotomy in patients with stenosis of ampulla of Vater:Three-year follow-up of exocrine pancreatic function and clinical symptoms显示文摘AIM: To investigate retrospectively the long-term effect of endoscopic sphincterotomy (ES) including exocrine pancreatic function in patients with stenosis of ampulla of Vater. METHODS: After diagnostic endoscopic retrograde cholangiopancreatography (ERCP) and ES because of stenosis of the ampulla of Vater (SOD Type Ⅰ), follow-up examinations were performed in 60 patients (mean follow-up time 37.7 mo). Patients were asked about clini-cal signs and symptoms at present and before interven-tion using a standard questionnaire. Before and after ES exocrine pancreatic function was assessed by determina-tion of immunoreactive fecal elastase 1. Serum enzymes indicating cholestasis as well as serum lipase and amy-lase were measured. RESULTS: Eighty percent of patients reported an im-provement in their general condition after ES. The fecal elastase 1 concentrations (FEC) in all patients increased significantly after ES. This effect was even more marked in patients with pathologically low concentrations (< 200 μg/g) of fecal elastase prior to ES. The levels of serum lipase and amylase as well as serum alcaline phosphatase (AP) and gamma-glutamyltranspeptidase (GGT) decreased signifi-cantly after ES. CONCLUSION: The results of this study demonstrate that patients with stenosis of the ampulla of Vater can be successfully treated with endoscopic sphincterotomy. The positive effect is not only indicated by sustained improvement of clinical symptoms and cholestasis but also by improvement of exocrine pancreatic function. | Nils Ewald Axel Michael Marzeion Reinhard Georg Bretzel Hans Ulrich Kloer Philip Daniel Hardt | 2007 | World Journal of Gastroenterology2007，13，6： | 5 |
| 7 | Highly Efficient Reprogramming to Pluripotency and Directed Differentiation of Human Cells with Synthetic Modified mRNA显示文摘 | Luigi Warren Philip D. Manos Tim Ahfeldt Yuin-Han Loh Hu Li Frank Lau Wataru Ebina Pankaj K. Mandal Zachary D. Smith Alexander Meissner George Q. Daley Andrew S. Brack James J. Collins Chad Cowan Thorsten M. Schlaeger Derrick J. Rossi | 2010 | Cell Stem Cell2010，，5： | 4 |
| 8 | Considerations for bariatric surgery in patients with cirrhosis显示文摘With the ever increasing global obesity pandemic, clinical burden from obesity related complications are anticipated in parallel. Bariatric surgery, a treatment approved for weight loss in morbidly obese patients, has reported to be associated with good outcomes, such as reversal of type two diabetes mellitus and reducing all-cause mortality on a long term basis. However, complications from bariatric surgery have similarly been reported. In particular, with the onslaught of non-alcoholic fatty liver disease(NAFLD) epidemic, in associated with obesity and metabolic syndrome, there is increasing prevalence of NAFLD related liver cirrhosis, which potentially connotes more risk of specific complications for surgery. Bariatric surgeons may encounter, either expectedly or unexpectedly, patients with non-alcoholic steatohepatitis(NASH) and NASH related cirrhosis more frequently. As such, the issues and considerations surrounding their medical care/surgery warrant careful deliberation to ensure the best outcomes. These considerations include severity of cirrhosis, liver synthetic function, portal hypertension and the impact of surgical factors. This review explores these considerations comprehensively and emphasizes the best approach to managing cirrhotic patients in the context of bariatric surgery. | George Boon-Bee Goh Philip R Schauer Arthur J McCullough | 2018 | World Journal of Gastroenterology2018，24，28： | 4 |
| 9 | Update on diagnosis and management of sepsis in cirrhosis: Current advances显示文摘Sepsis and septic shock are catastrophic disease entities that portend high mortality in patients with cirrhosis.In cirrhosis,hemodynamic perturbations,immune dysregulation,and persistent systemic inflammation with altered gut microbiota in the background of portal hypertension enhance the risk of infections and resistance to antimicrobials.Patients with cirrhosis develop recurrent lifethreatening infections that progress to multiple organ failure.The definition,pathophysiology,and treatment options for sepsis have been ever evolving.In this exhaustive review,we discuss novel advances in the understanding of sepsis,describe current and future biomarkers and scoring systems for sepsis,and delineate newer modalities and adjuvant therapies for the treatment of sepsis from existing literature to extrapolate the same concerning the management of sepsis in cirrhosis.We also provide insights into the role of gut microbiota in initiation and progression of sepsis and finally,propose a treatment algorithm for management of sepsis in patients with cirrhosis. | Cyriac Abby Philips Rizwan Ahamed Sasidharan Rajesh Tom George Meera Mohanan Philip Augustine | 2020 | World Journal of Hepatology2020，12，8： | 2 |
| 10 | Appropriateness of systemic treatments in unresectable metastatic well-differentiated pancreatic neuroendocrine tumors显示文摘AIM:To evaluate systemic treatment choices in unresectable metastatic well-differentiated pancreatic neuroendocrine tumors(PNETs)and provide consensus treatment recommendations.METHODS:Systemic treatment options for pancreatic neuroendocrine tumors have expanded in recent years to include somatostatin analogs,angiogenesis inhibitors,inhibitors of mammalian target of rapamycinand cytotoxic agents.At this time,there is little data to guide treatment selection and sequence.We therefore assembled a panel of expert physicians to evaluate systemic treatment choices and provide consensus treatment recommendations.Treatment appropriateness ratings were collected using the RAND/UCLA modified Delphi process.After studying the literature,a multidisciplinary panel of 10 physicians assessed the appropriateness of various medical treatment scenarios on a 1-9 scale.Ratings were done both before and after an extended discussion of the evidence.Quantitative measurements of agreement were made and consensus statements developed from the second round ratings.RESULTS:Specialties represented were medical and surgical oncology,interventional radiology,and gastroenterology.Panelists had practiced for a mean of15.5 years(range:6-33).Among 202 rated scenarios,disagreement decreased from 13.2%(26 scenarios)before the face-to-face discussion of evidence to 1%(2)after.In the final ratings,46.5%(94 scenarios)were rated inappropriate,21.8%(44)were uncertain,and30.7%(62)were appropriate.Consensus statements from the scenarios included:(1)it is appropriate to use somatostatin analogs as first line therapy in patients with hormonally functional tumors and may be appropriate in patients who are asymptomatic;(2)it is appropriate to use everolimus,sunitinib,or cytotoxic chemotherapy therapy as first line therapy in patients with symptomatic or progressive tumors;and(3)beyond first line,these same agents can be used.In patients with uncontrolled secretory symptoms,octreotide LAR doses can be titrated up to 60 mg every4 wk or up to 40 mg every 3 or 4 wk.CONCLUSION:Using the Delphi process allowed physician experts to systematically obtain a consensus on the appropriateness of a variety of medical therapies in patients with PNETs. | Jonathan R Strosberg George A Fisher Al B Benson Lowell B Anthony Bulent Arslan John F Gibbs Edward Greeno Renuka V Iyer Michelle K Kim William J Maples Philip A Philip Edward M Wolin Dasha Cherepanov Michael S Broder | 2015 | World Journal of Gastroenterology2015，21，8： | 2 |
| 11 | Oxygen desaturation during sleep in hepatopulmonary syndrome显示文摘 | David T. Palma George M. Philips Miguel R. Arguedas Susan M. Harding Michael B. Fallon | 2008 | Hepatology2008，，4： | 2 |
| 12 | Prospective Study on Circulating MicroRNAs and Risk of Myocardial Infarction显示文摘 | Anna Zampetaki Peter Willeit Lindsey Tilling Ignat Drozdov Marianna Prokopi Jean-Marie Renard Agnes Mayr Siegfried Weger Georg Schett Ajay Shah Chantal M. Boulanger Johann Willeit Philip J. Chowienczyk Stefan Kiechl Manuel Mayr | 2012 | Journal of the American College of Cardiology2012，，： | 2 |
| 13 | A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer显示文摘 | Ramesh K. Ramanathan Chandra P. Belani Deepti A. Singh Michael Tanaka Heinz-Josef Lenz Yun Yen Hedy L. Kindler Syma Iqbal Jeff Longmate Philip C. Mack Georg Lurje Regina Gandour-Edwards Janet Dancey David R. Gandara | 2009 | Cancer Chemotherapy and Pharmacology2009，，4： | 2 |
| 14 | An international, multicenter phase II trial of bortezomib in patients with hepatocellular carcinoma显示文摘 | George P. Kim Michelle R. Mahoney Daniel Szydlo Tony S. K. Mok Robert Marshke Kyle Holen Joel Picus Michael Boyer Henry C. Pitot Joseph Rubin Philip A. Philip Anna Nowak John J. Wright Charles Erlichman | 2012 | Investigational New Drugs2012，，1： | 2 |
| 15 | Efficacy and tolerability of montelukast alone or in combination with loratadine in seasonal allergic rhinitis: a multicenter, randomized, double-blind, placebo-controlled trial performed in the fall 显示文摘 | Anjuli Nayak George Philip | 2001 | Allergy Asthma & Immunology2001，88，6： | 1 |
| 16 | Chicken TLR21 acts as a functional homologue to mammalian TLR9 in the recognition of CpG oligodeoxynucleotides显示文摘 | Robert Brownlie Jianzhong Zhu Brenda Allan George K. Mutwiri Lorne A. Babiuk Andrew Potter Philip Griebel | 2009 | Molecular Immunology2009，，15： | 1 |
| 17 | 2010 ACCF/AHA Guideline for Assessment of Cardiovascular Risk in Asymptomatic Adults显示文摘 | Philip Greenland Joseph S. Alpert George A. Beller Emelia J. Benjamin Matthew J. Budoff Zahi A. Fayad Elyse Foster Mark A. Hlatky John McB. Hodgson Frederick G. Kushner Michael S. Lauer Leslee J. Shaw Sidney C. Smith Allen J. Taylor William S. Weintraub N | 2010 | Journal of the American College of Cardiology2010，，25： | 1 |
| 18 | Current status quo on COVID-19 including chest imaging显示文摘With each day the number coronavirus disease 2019(COVID-19)cases continue to rise rapidly and our imaging knowledge of this disease is expeditiously evolving.The role of chest computed tomography(CT)in the screening or diagnosis of COVID-19 remains the subject of much debate.Despite several months having passed since identifying the disease,and numerous studies related to it,controversy and concern still exists regarding the widespread use of chest CT in the evaluation and management of COVID-19 suspect patients.Several institutes and organizations around the world have released guidelines,recommendations and statements against the use of CT for diagnosing or screening COVID-19 infection and advocating its use only for those cases with a strong clinical suspicion of complication or an alternate diagnosis.However,these guidelines and recommendations are in disagreement with majority of the widely available literature,which strongly favour CT as a pivotal tool in the early diagnosis,management and even follow-up of COVID-19 infection.This article besides comprehensively reviewing the current status quo on COVID-19 disease in general,also writes upon the current consensus statements/recommendations on the use of diagnostic imaging in COVID-19 as well as highlighting the precautions and various disinfection procedures being employed world-wide at the workplace to prevent the spread of infection. | Rishi Philip Mathew Merin Jose Vinayak Jayaram Paul Joy Danny George Maria Joseph TeenaSleeba Ajith Toms | 2020 | World Journal of Radiology2020，12，12： | 1 |
| 19 | AIN-93 purified diets for laboratory rodents:Final report of the American Institute of Nutrition Ad Hoc Writing committee on the reformulation of the AIN-76 Ardent diet显示文摘 | Philip GE Forrest HN George CF | 1993 | J Nutr1993，123，： | 1 |
| 20 | In Vivo Magnetic Resonance Imaging of Coronary Thrombosis Using a Fibrin-Binding Molecular Magnetic Resonance Contrast Agent显示文摘 | René M. Botnar Arno Buecker Andrea J. Wiethoff Edward C. Parsons Marcus Katoh George Katsimaglis Robert M. Weisskoff Randall B. Lauffer Philip B. Graham Rolf W. Gunther Warren J. Manning Elmar Spuentrup | 2004 | Circulation2004，，11： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员